Product Description
FRM-6308 (FORUM Pharmaceuticals, Inc.) is a novel, potent and highly selective PDE10A inhibitor that has also demonstrated antipsychotic efficacy in rodent models (conditioned avoidance responding, stimulant-induced locomotor activity and prepulse inhibition tests). FRM-6308 was active at doses that did not produce decreases in spontaneuous locomotor activity or catalepsy (unpublished data). (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028314/)
Mechanisms of Action: PDE10 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: FORUM
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers|Schizophrenia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| EVP-6308-003 | P1 |
Completed |
Schizophrenia |
2014-12-01 |
2019-03-20 |
Treatments |
|
| EVP-6308-002 | P1 |
Completed |
Healthy Volunteers |
2014-06-01 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|